期刊
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
卷 37, 期 1, 页码 1227-1240出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14756366.2022.2062337
关键词
Kinase inhibitors; pancreatic cancer; molecular docking; benzofuran synthesis; apoptotic agents
资金
- Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia [PNURSP2022R25]
- [22UQU4290565DSR010]
In this study, a hybridisation strategy was used to design novel CDK2 type II inhibitors, which showed promising inhibitory activity and antiproliferative activity against cancer cell lines. The designed compounds have the potential to be used in cancer treatment with low toxicity to normal cells.
In the current work, a hybridisation strategy was adopted between the privileged building blocks, benzofuran and piperazine, with the aim of designing novel CDK2 type II inhibitors. The hybrid structures were linked to different aromatic semicarbazide, thiosemicarbazide, or acylhydrazone tails to anchor the designed inhibitors onto the CDK2 kinase domain. The designed compounds showed promising CDK2 inhibitory activity. Compounds 9h, 11d, 11e and 13c showed potent inhibitory activity (IC50 of 40.91, 41.70, 46.88, and 52.63 nM, respectively) compared to staurosporine (IC50 of 56.76 nM). Moreover, benzofurans 9e, 9h, 11d, and 13b showed promising antiproliferative activities towards different cancer cell lines, and non-significant cytotoxicity on normal lung fibroblasts MRC-5 cell line. Furthermore, a cell cycle analysis as well as Annexin V-FITC apoptosis assay on Panc-1 cell line were performed. Molecular docking simulations were performed to explore the ability of target benzofurans to adopt the common binding pattern of CDK2 type II inhibitors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据